Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis. Results provide clinical evidence that CardiolRx™ reduces inflammation-driven structural damage in the heart, an important cause of heart failure progression. The ARCHER data strengthen the scientific and... Read More

Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property protection in the world's largest pharmaceutical market. This allowance fortifies Cardiol's global intellectual property portfolio, adding to granted and pending patent applications in Europe, Japan, Canada, Australia, and... Read More

The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis. Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a notable improvement in extracellular volume and a significant reduction in left ventricular mass. The Company will host a webcast conference call on December 1, 2025, to discuss... Read More

MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA. New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardiology conference in November 2025. Next-generation therapy CRD-38 for heart failure... Read More

MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA. New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardiology conference in November 2025. Next-generation therapy CRD-38 for heart failure... Read More

Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will participate in a Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference in Boston, MA, on... Read More

Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx™ over placebo. Reduction in ECV was associated with improvements across multiple pre-specified cardiac magnetic resonance imaging (CMR) endpoints, including a significant reduction in LV mass. The ARCHER trial results provide compelling clinical proof of concept for CardiolRx™ and... Read More

ARCHER is designed to assess the impact of CardiolRx™ on cardiac magnetic resonance imaging parameters that measure heart dysfunction and edema/fibrosis-key measurements used to predict prognosis in myocarditis patients. Acute myocarditis is a potentially life-threatening condition affecting the heart muscle (myocardium) and is characterized by chest pain, shortness of breath, fatigue, rapid or irregular heartbeat... Read More

Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast on May 28, 2025.... Read More

Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on May 28, 2025, at 4:30 p.m. EDT.... Read More

Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experience Toronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that... Read More

Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago. Based on a successful end-of-Phase II meeting with the US FDA and subject to MAVERIC outcomes, Cardiol believes the results from MAVERIC will support a New Drug Application. Data from Cardiol's Phase II MAvERIC-Pilot study presented at the American Heart... Read More

Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patients with acute myocarditis, with topline data expected in Q2 2025 CardiolRx™ granted U.S. FDA Orphan Drug Designation... Read More

Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will present at the TD Cowen 45th Annual Health Care Conference in Boston, MA, on March 5, 2025, at 11:10 a.m.... Read More

Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failure Toronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies... Read More

Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will present at the Oppenheimer 35 th Annual Healthcare Life Sciences Conference... Read More

Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week study Episodes of pericarditis per year substantially reduced MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2 and the Phase III MAVERIC-3 clinical trials Toronto, Ontario--(Newsfile Corp. - November 18, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the "... Read More

MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with the Company's planned Phase III program. Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research... Read More

Oakville, Ontario--(Newsfile Corp. - October 11, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company") , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that, further to its successfully completed public offering of an aggregate of 8,437,500... Read More

Oakville, Ontario--(Newsfile Corp. - October 10, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company") , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, confirmed today that it has successfully closed its previously announced public offering (the " Offering ") of... Read More

Oakville, Ontario--(Newsfile Corp. - October 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company") , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the pricing of its previously announced public offering (the " Offering ") of 8,437,500 Class A... Read More

Toronto, Ontario--(Newsfile Corp. - October 8, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company") , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce the Company has filed a preliminary prospectus supplement (the " Supplement ") to its short... Read More

Toronto, Ontario--(Newsfile Corp. - September 24, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced it has achieved the target patient enrollment of 100 patients in "ARCHER", its Phase II... Read More

Full clinical data will be reported in an oral presentation at the premier global event for advancements in cardiovascular science and medicine on November 18, 2024 Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and... Read More

Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its annual general and special meeting of shareholders (the "Meeting") held... Read More

Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc . ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annual General and Special Meeting of Shareholders (the "AGM") will be... Read More

Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis pain CardiolRx™ also shown to reduce inflammation in patients with elevated CRP 89% of patients have continued into the extension phase of the study Toronto, Ontario--(Newsfile Corp. - June 13, 2024) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences... Read More

Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute myocarditis ARCHER trial rationale and design also accepted for publication in the journal ESC Heart Failure ARCHER trial has now exceeded 85% of target patient enrollment MAvERIC-Pilot Phase II study investigating CardiolRx™ for recurrent... Read More

Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in patients with recurrent pericarditis, with topline results expected in Q2 2024 CardiolRx™ granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis, which includes recurrent pericarditis Exceeded 50% enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patients with acute myocarditis; study expected to reach... Read More

Topline Results Expected in Q2 2024 Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced completion of patient enrollment in its Phase II open-label... Read More

Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II Study Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart... Read More

Toronto, Ontario--(Newsfile Corp. - January 24, 2024) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that it received notice on January 23, 2024 from The Nasdaq Stock Market LLC ("Nasdaq")... Read More

Toronto, Ontario--(Newsfile Corp. - January 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it has exceeded 50% patient enrollment for ARCHER, the Company's Phase II,... Read More

MAvERIC-Pilot is a Phase II Study in Recurrent Pericarditis and is Anticipated to Complete Patient Recruitment during Q1 2024 Toronto, Ontario--(Newsfile Corp. - December 5, 2023) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment... Read More

Toronto, Ontario--(Newsfile Corp. - November 16, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today that study results demonstrated an experimental model of pericarditis induces mesothelial to... Read More

Toronto, Ontario--(Newsfile Corp. - November 1, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it has exceeded 50% of the patient enrollment target for its Phase II open-label... Read More

Toronto, Ontario--(Newsfile Corp. - October 20, 2023) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that on October 19, 2023, it received a notice (the "Notice") from the Nasdaq Stock Market LLC... Read More

Results Demonstrate the Active Pharmaceutical Ingredient in Cardiol's Novel CRD-38 Formulation Attenuates Harmful Fat Distribution and Key Markers of Cardiac Inflammation and Remodelling Data Presented at the Heart Failure Society of America Annual Scientific Meeting 2023 Toronto, Ontario--(Newsfile Corp. - October 10, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a... Read More

Toronto, Ontario--(Newsfile Corp. - September 26, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that Cardiol's President and CEO, David Elsley, will present a company overview today... Read More

Recruitment Accelerating and Full Patient Enrollment Anticipated to be Completed During Q3 2024, up to Six Months Ahead of Schedule Multi-Center, International, Double-blind, Placebo-controlled Trial Randomizing 100 Patients Toronto, Ontario--(Newsfile Corp. - September 19, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the... Read More

Toronto, Ontario--(Newsfile Corp. - August 9, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that Cardiol's President and CEO, David Elsley, will present a company overview which will... Read More

Oakville, Ontario--(Newsfile Corp. - August 8, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that it received notice on August 7, 2023 from The Nasdaq Stock Market LLC ("Nasdaq") stating the... Read More

Oakville, Ontario--(Newsfile Corp. - June 29, 2023) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live... Read More

Oakville, Ontario--(Newsfile Corp. - June 27, 2023) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today is pleased to announce that the Company's virtual Annual General Meeting of Shareholders (the "AGM")... Read More

Initiated patient enrollment in a Phase II open-label clinical trial investigating the safety, tolerability, and efficacy of CardiolRx™ in patients with recurrent pericarditis - a debilitating heart disease associated with chest pain, shortness of breath and fatigue, resulting in markedly reduced quality of life, emergency department visits, and hospitalizations Initiated patient enrollment in the ARCHER Trial - a Phase II... Read More

Results Demonstrate Cannabidiol Improved Cardiac Function, Reduced its Inflammatory State, and Prevented the Development of Hypertrophy and Fibrosis in Heart Tissue Data Presented at The American College of Cardiology's 72 nd Annual Scientific Session Together with the World Congress of Cardiology Oakville, Ontario--(Newsfile Corp. - March 7, 2023) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the... Read More

The Cleveland Clinic Recruits First Participant in the Multi-center U.S. Study Oakville, Ontario--(Newsfile Corp. - January 17, 2023) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases, announced today that the... Read More

The Cleveland Clinic and the Mayo Clinic Study Sites have been Initiated and are Eligible to Recruit Participants Initiation of Additional U.S. Cardiovascular Research Centers is Planned for Q1, 2023 Oakville, Ontario--(Newsfile Corp. - December 12, 2022) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical... Read More

Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases, announced today that it will discontinue the LANCER trial due to lack of eligible patients to support recruitment and will prioritize its Phase II clinical programs... Read More

Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of cardiovascular diseases ("CVD"), announced today that study results demonstrate the active pharmaceutical ingredient ("API") in CardiolRx™ inhibits and also promotes the reversal of... Read More

Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of cardiovascular diseases ("CVD"), announced today that an abstract submitted by its international research collaborators from Houston Methodist DeBakey Heart & Vascular Center was... Read More

Cardiol Therapeutics Inc . ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases ("CVD"), announced today that the first patient has been enrolled in ARCHER , the Company's Phase II, multi-center, international,... Read More

Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases ("CVD"), announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast, on June 28,... Read More

Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases ("CVD"), is pleased to announce that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on June 28,... Read More

Cardiol Therapeutics Inc . ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of cardiovascular disease, is pleased to announce that it has entered into a sales agreement (the "ATM Agreement" ) with Canaccord Genuity LLC and Cantor Fitzgerald & Co. (the "Sales... Read More

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that its Board of Directors has appointed Teri Loxam and Chris Waddick to serve as directors, effective immediately. Ms. Teri Loxam has over... Read More

Third IND authorization for CardiolRx™ in cardiovascular disease Study to run in parallel with Company's multi-national Phase II acute myocarditis trial, expected to commence imminently CardiolRx™ is now eligible for orphan drug status in two indications Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical... Read More

Expanded the Phase II/III LANCER clinical trial in patients with cardiovascular disease (CVD), or significant CVD risk factors, who are hospitalized with COVID-19 Received authorization from the FDA to proceed with the Company's IND to commence a Phase II multi-national clinical trial in patients with acute myocarditis Made strategic appointments to senior management team Listed on the NASDAQ stock exchange Ended 2021 with... Read More

Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that Cardiol's Chief Medical Officer, Dr. Andrew Hamer, will be participating in a panel discussion entitled "New World Order for Endo/CV/Renal Disease" at... Read More

Cardiol Therapeutics Inc. ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that it has received final approval from The Nasdaq Capital Market LLC ("NASDAQ") to list its common shares on NASDAQ. The Company's shares will begin trading on August 10, 2021, under the... Read More